A pharmaceutical company in China has been accused of implementing unfair high -priced sales preparations. After two interviews with Chinese officials, the price of the involved preparations from an increase of 2,300 yuan (RMB, the same below, the same, 429 S $ 429), Drop to 123 yuan.
China National Medical Insurance Bureau on Thursday (January 4) on the WeChat public account that the market regulatory authorities are in the first biochemical abuse of drugs involved in the enterprise involved.The prime B market governs its position and implements an administrative penalty for the behavior of unfair high -priced sales preparations.
The Medical Insurance Bureau said that in the first half of 2023, the relevant departments discovered that the first biochemistry of the medicine was suspected of using Wuhan Huihai Pharmaceutical, Wuhan Kodo Pharmaceutical, and Hubei Minkang Pharmaceutical.Times, at the same time, the price of polyphonin B hanging sulfuric acid B -hanging nets involved in the case is illegally lifted to 2303 yuan/branch, which is sold at a high price of dozens of times higher than foreign foreign prices.The sales amount was more than 4 billion yuan, and the huge improper benefits were obtained.
The National Medical Insurance Administration intervened for this, and first interviewed the first biochemistry in the medicine in June 2023.After reminding, the company promised that the price of polyphonin B hanging sulfurine B hanging nets in various places will be reduced from 2303-2918 yuan per branch to 270 yuan per branch.Internet price.
The Medical Insurance Bureau said: "After the relevant violations of laws and regulations have been verified, the State Medical Insurance Bureau interviewed the first biochemistry for the second time and urged the performance of price rectification.The price of bacterial B hanging network has further reduced to 123 yuan/branch, a cumulative decrease of more than 95.8%.It is expensive to remove 17 drugs, such as the procurement of the intermediate links of the procurement of the drug drug and the virtual increase in the flow of drugs, and the active reduction of 17 drugs, including sulfate sulfur protein injection, with an average decrease of 25.5%.
The first biochemistry was established in 1994, and in 2010 it became a wholly -owned subsidiary of Shanghai Medical Group.According to Shanghai Pharmaceutical's official website, the first biochemical product of the drug covers biochemical raw materials, chemical raw materials and natural drug extracts and its sterile pink needles.
